Pharmaceutical Preparations · DE · CIK 1395937
Syndax Pharmaceuticals develops combination cancer therapies, including revumenib and axatilimab
Comparable business profile · signals at a glance
In the 90 days to Feb 9, 2026: 2 sold $628K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 9, 2026 | Metzger Michael AChief Executive Officer | Sell | 17,159 | $21.03 | $361K |
| Feb 9, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 3,410 | $21.03 | $72K |
| Feb 6, 2026 | Metzger Michael AChief Executive Officer | Sell | 7,412 | $20.62 | $153K |
| Feb 6, 2026 | Goldan Keith A.Chief Financial Officer | Sell | 2,082 | $20.62 | $43K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.